Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

Key facts

Sponsor

Betta Pharmaceuticals Co., Ltd.

Principal Investigator

Zhang Yi Ping, M.D.

Zhejiang Cancer Hospital

Intervention

Icotinib of routine dose(drug)

Enrollment

180 enrolled

Eligibility

18-75 years · All sexes

Timeline

2012 – 2016

Study locations (17)

• Fujian Hospital for Chest Tumors & Tuberculosis Diseases, Fuzhou, Fujian, China
• Fujian Provincal Hospital, Fuzhou, Fujian, China
• Fujian Provincal Cancer Hospital, Fuzhou, Fujian, China
• The second hospital of Xiamen City, Xiamen, Fujian, China
• Hunan Provincal Cancer Hospital, Changsha, Hunan, China
• The Second People's Hospital of Sichuan, Chengdu, Sichuan, China
• Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
• The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
• The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
• Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
• Zhejiang Traditional Chinese Medical Hospital, Hangzhou, Zhejiang, China
• Zhejiang Hospital, Hangzhou, Zhejiang, China
• Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
• Yinzhou People's Hospital, Ningbo, Zhejiang, China
• Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, Zhejiang, China
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for NON RARE IN EUROPE: Non-small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06878274
  Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
  Centre hospitalier de l'Université de Montréal (CHUM)
• RECRUITINGPHASE3NCT07251582
  Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
  Hunan Province Tumor Hospital
• RECRUITINGPHASE2NCT06946797
  A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07086456
  Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
  Sun Yat-sen University
• RECRUITINGNANCT07086300
  Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
  Kong Fanming
• RECRUITINGPHASE2NCT06620835
  Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
  Groupe Francais De Pneumo-Cancerologie
• RECRUITINGPHASE1, PHASE2NCT06922591
  Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
  Tango Therapeutics, Inc.
• RECRUITINGPHASE3NCT07050043
  Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
  Dr Arvindran A/L Alaga

See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →